Alunacedase alfa

阿鲁纳西酶 α

Report date: 2025/12/26 20:01:33

Base Information

Drug NameAlunacedase alfa
Drug Alias NamerhACE2APN-01GSK-2586881
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionAngiotensin II degraders
TargetsAngiotensin II
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Cardiovascular DiseasesKidney Diseases +[7
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesRussian Federation +[9
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesApeiron Biologics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Cardiovascular DiseasesKidney Diseases +[7

Other Information

ATC CodeN/A
Related LinksN/A